Skip to content
Psychiatrist.com Logo
  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Advanced Search

Menu

  • JCP
  • PCC
  • News
  • CME
  • About
  • Authors & Reviewers
  • Sign In
  • Subscribe
Sign in! Subscribe

Clinical Topics

View All
  • Addiction
  • ADHD
  • Anxiety
  • Bipolar Disorder
  • Depression
  • Emerging Approaches in Schizophrenia
  • Movement Disorders
  • Neurology
  • OCD
  • Psychopharmacology
  • PTSD and Trauma
  • Schizophrenia/Schizoaffective Disorders
  • Sleep
  • Tardive Dyskinesia
  • View All

Collections

View All
  • Academic Highlights
  • Auvelity: Information from Industry
  • Banner Alzheimer’s Institute
  • Clinical & Practical Psychopharmacology
  • Early Career Psychiatrists
  • Focus on Childhood and Adolescent Mental Health
  • Focus on Geriatric Psychiatry
  • Focus on Psychotherapy
  • Focus on Suicide
  • Focus on Psychosis
  • Focus on Women’s Mental Health
  • Rounds in the General Hospital
  • View All
Back to top Open menu arrow
Download Free PDF

Save Save

Share Share

Cite Cite

Reprints
Sections
No sections available
Primary Care Companion for CNS Disorders Primary Care Companion for CNS Disorders

The Primary
Care Companionfor CNS Disorders

Access icon
Schizophrenia/Schizoaffective Disorders

Letter to the Editor October 16, 2006

Careful Monitoring for Agranulocytosis During Carbamazepine Treatment

Joan M. Daughton, M.D. ; Prasad R. Padala, M.D. ; Teri L. Gabel, Pharm.D.

Prim Care Companion J Clin Psychiatry 2006;8(5):310-311

Article Abstract

Letter to the Editor

Careful Monitoring fo Agranulocytosis During Carbamazepine Treatment

Download Free PDF

This PDF is free for all visitors!

Save Save

Share Share

Cite Cite

Related News Articles

Weekly Mind Reader: Delusion vs. Reality Weekly Mind Reader: A Question of Ethics Genetics, Income, and Opportunity Shape Socio-Economic Outcomes

Sponsored

PsychCase360: Choosing the Right Long-Acting Injectable for Patients With Schizophrenia
Explore two real-world schizophrenia cases with Roueen Rafeyan, MD and Melissa Vitale, PMHNP as they discuss challenges with medication adherence, transitioning to long-acting injectables (LAIs), and personalizing treatment strategies to improve patient outcomes.

Related JCP Articles

Clozapine Monitoring in the Post-REMS World: Some Guidance for Clinicians Xanomeline and Trospium Chloride for Agitation Associated With Schizophrenia Pharmacokinetics of Olanzapine Intranasal Spray vs Olanzapine IM

Related PCC Articles

Substance Use in Pregnant and Postpartum Women Low-Dose Clozapine in Schizophrenia With Aggression Recurrent Catatonia Following Hypothyroidism

Vol 27 • 2025 • Number 2

Read the Current Issue

Original Research

What Internists and Neurologists Know and Think About Catatonia

Original Research

Psychological Morbidities in Hospital Staff During Nipah Virus

Systematic Review

Exercise and Fibromyalgia Pain

Rounds in the General Hospital

Managing Anxiety, Agitation, and Pain in Critically Ill Patients

Review Article

Quality Indicators in Community Mental Health Services: A Scoping Review

Case Report

Is My Patient Diverting Their Lorazepam?

View current Issue

Related Articles

JCP
Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?
Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...
Xintong Mu , Hiroyoshi Takeuchi
JCP
Asenapine, Aggression, and Affinity
Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.
Rif S. El-Mallakh
JCP
A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole
Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.
Florian Naudet , André Gillibert , Barbara Mintzes , et al

Watch the New PsychCase360

Explore two real-world schizophrenia cases

Subscribe to read
more articles

Subscribe
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

ELSEWHERE:

  • ABOUT
  • ADVERTISERS
  • MEDIA RELATIONS
  • REPRINTS & PERMISSIONS
  • CONTACT US
  • CUSTOMER SUPPORT

FOLLOW US:

  • X
  • FACEBOOK
  • INSTAGRAM
  • LINKEDIN
  • SIGN IN

  • JOIN THE EMAIL LIST


SUBSCRIBE NOW
An image of the Psychiatrist.com logo mark
  • Privacy Policy
  • Terms of Use
  • Physicians Postgraduate Press, Inc.
  • JCP ISSN: Online 1555-2101, Print 0160-6689
  • PCC ISSN: Online 2155-7780, Print 2155-7772
  • MedFair.com US Patent No. 684794
  • © Copyright 2025 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians
  • Sitemap